Turning the Spotlight on Apathy: Identification and Treatment in Schizophrenia Spectrum Disorders.

42 Compared to placebo, one phase 2b RCT 43 reported that roluperidone, which primarily targets 5HT 2A and sigma 2 receptors, significantly reduced experiential domain symptoms, whereas another roluperidone RCT found a nominally significant reduction in the experiential domain. 44 Adjunctive Medication Several drugs have been tested as adjunctive medication to AP. 30 Two RCTs, one severely underpowered, 45 compared the monoamine oxidase B inhibitor rasagiline 46 and the selective serotonin reuptake inhibitor citalopram 45 to placebo and found a significant reduction in apathy and the experiential domain, respectively.

also in 7,732 other papers